Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10966518 | Vaccine | 2014 | 6 Pages |
Abstract
Among three main subtypes of the tick-borne encephalitis virus (TBEV), the Siberian subtype is currently dominant in a majority of the endemic regions of Russia. However, inactivated vaccines are based on TBEV strains of the heterologous Far Eastern or the European subtypes isolated 40-77 years ago. To analyze the efficacy of the available vaccines against currently prevailing TBEV isolates of the Siberian subtype, mice were immunized subcutaneously three times (one group per each vaccine). The expression of seven cytokine genes was determined using RT-PCR. Sera were studied using homologous and heterologous ELISA, hemagglutination inhibition (HI) and neutralization tests with TBEV strains of the Far Eastern, Siberian and European subtypes. Cross-protective efficacy of the vaccines was evaluated with the TBEV strain 2689 of Siberian subtype isolated from an ixodid tick from the Novosibirsk, South-Western Siberia, Russia in 2010. The cytokine gene expression profile indicates a predominantly Th2 response due to exogenous antigen presentation. Titers for homologous combinations of vaccine strain and strain in ELISA, HI and neutralization tests exceeded those for heterologous antigen-antibody pairs. Despite antibody detection by means of ELISA, HI and neutralization tests, the mouse protection afforded by the vaccines differed significantly. Complete protection of mice challenged with 100 LD50 virus of the Siberian subtype was induced by the vaccine “Encevir” (“Microgen”, Tomsk, Russia). The minimal immunization doze (MID50) of “Encevir” protecting 50% of the mice was less than 0.0016Â ml. Partial protective effect of vaccines produced in Moscow, Russia and Austria revealed MID50 within recommended intervals (0.001-0.017Â ml). However, the MID50 for the vaccine “Encepur” (Novartis, Germany) 0.04Â ml exceeded acceptable limits with total loss of mice immunized with vaccine diluted 32, 100 and 320 fold. These results suggest regular evaluation of TBEV vaccines in regions where heterologous virus subtypes prevail.
Keywords
TNFLethal dosesTick-borne flavivirusTCIDTBEvAFMLD50Protective effectTemEnzyme-linked immunosorbent assayELISANeutralization testreverse transcriptionCytokinestumor necrosis factorhemagglutination inhibitionTransmission electron microscopyatomic force microscopyInactivated vaccinepolymerase chain reactionPCR
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
O.V. Morozova, V.N. Bakhvalova, O.F. Potapova, A.E. Grishechkin, E.I. Isaeva, K.V. Aldarov, D.V. Klinov, M.F. Vorovich,